Measuring levels of protein CD25 in blood and urine can help determine if ANCA-associated vasculitis is affecting patients’ kidneys, a study…
Articles by Patricia Inacio, PhD
Differences in red blood cell size may help predict how active a blood vessel condition called granulomatosis with polyangiitis will be, and…
Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who receive daily oral cyclophosphamide have increased bone marrow toxicity and tend…
Tailoring infusions of Rituxan (rituximab) according to ANCA status and/or levels of CD19-positive lymphocytes has no significant impact on…
Increases in the Birmingham Vasculitis Activity Score (BVAS) may work as an independent risk predictor for cardiovascular  disease (CVD)-related deaths…
In patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), Rituxan (rituximab) may lead to general decrease in antibody levels,…
The Phase 3 ADVOCATE trial, evaluating ChemoCentryx‘s investigational drug avacopan (formerly CCX168) for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated…